Health. Bronchiolitis: Beyfortus is effective in preventing serious infections, according to a study.

Respiratory syncytial virus (RSV) causes respiratory infections in newborns and infants that can develop into bronchiolitis, which can, in some cases, lead to severe complications.

A large-scale study, analyzing data from 27 studies conducted during the 2023-2024 season in five countries (France, Italy, Luxembourg, Spain and the United States), demonstrates that Beyfortus, a preventive treatment using monoclonal antibodies (a protein designed in the laboratory that mimics the immune system's ability to fight viruses), significantly reduces the risk of hospitalization linked to RSV.

Particularly encouraging results

The figures speak for themselves: nirsevimab reduces the risk of hospitalization due to RSV by 83%, intensive care admissions by 81%, and lower respiratory tract infections by 75% in children under one year of age. Its efficacy is slightly higher in infants over 3 months old (81%) compared to younger children (76%).

The study authors emphasize that these results support the use of nirsevimab as an essential intervention to prevent severe forms of RSV in infants. They note, however, that the included studies were observational, which could introduce certain biases related to factors such as underlying health conditions, socioeconomic status, or regional differences in access to care.

Please note: Beyfortus prevents the RSV virus from infecting the body by neutralizing it and protects newborns and infants within a few days of injection. Only one injection is required.